Published in AIDS Weekly and Law, May 13th, 2004
The HOPS investigators agreed that the Novir price increase was unprecedented, unethical and threatens access to care across the United States. In the letter, the investigators stated that Abbott's pledge to freeze the price of Novir to publicly funded drug programs failed to address the full impact of the policy, calling the Novir price increase "highly injurious to the U.S. HIV treatment and research...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly and Law
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.